Patient-Derived Organoids (PDOs) are cutting-edge 3D in vitro models developed directly from tumor tissue. In addition to cellular heterogeneity and microarchitecture, these self-organizing structures maintain the original tumor's genetic, phenotypic, and functional characteristics. In order to preserve cancer stem cell populations and tumor-specific behavior, Apricell uses optimized protocols and defined media. Personalized drug screening, biomarker discovery, and modeling of treatment response are possible through PDOs, which bridge the gap between the biology of patients and preclinical testing.